Heterozygous Knockout of Transforming Growth Factor-β1 Protects Dahl S Rats Against High Salt-induced Renal Injury

Overview

Journal Physiol Genomics

Publisher American Physiological Society

Specialties Genetics
Molecular Biology

Date 2012 Dec 20

PMID 23249995

Citations 15

Authors

Chun Cheng Andy Chen

Aron M Geurts

Howard J Jacob

Fan Fan

Richard J Roman

Affiliations

Soon will be listed here.

Abstract

The present study employed a zinc-finger nuclease strategy to create heterozygous knockout (KO) rats for the transforming growth factor-β1 (Tgfb1) gene on the Dahl SS/Jr genetic background (TGF-β1(+/-) Dahl S). Intercrossing TGF-β1(+/-) rats did not produce any homozygous KO rats (66.4% +/-, 33.6% +/+), indicating that the mutation is embryonic lethal. Six-week-old wild-type (WT) littermates and TGF-β1(+/-) Dahl S rats were fed a 0.4% (low salt, LS) or 8% NaCl (high salt, HS) diet for 5 wk. Renal cortical expression of TGF-β1, urinary TGF-β1 excretion, proteinuria, glomerular injury and tubulointerstitial fibrosis, and systolic blood pressure were similar in WT and TGF-β1(+/-) Dahl S rats maintained on the LS diet. The expression and urinary excretion of TGF-β1 increased to a greater extent in WT than in TGF-β1(+/-)Dahl S rats fed an HS diet for 1 wk. Systolic blood pressure rose by the same extent to 235 ± 2 mmHg in WT and 239 ± 4 mmHg in TGF-β1(+/-) Dahl S rats fed a HS diet for 5 wk. However, urinary protein excretion was significantly lower in TGF-β1(+/-) Dahl S than in the WT animals. The degree of glomerular injury and renal cortical and outer medullary fibrosis was markedly less in TGF-β1(+/-) than in WT rats. These findings suggest that the loss of one copy of the TGF-β1 gene blunts the increase in renal TGF-β1 protein expression and slows the progression of proteinuria, glomerulosclerosis, and renal interstitial fibrosis in Dahl S rats fed an HS diet independently of changes in blood pressure.

Citing Articles

Intrarenal Dopaminergic System Is Dysregulated in SS- Rats.

Ashraf U, Atari E, Alasmari F, Waghulde H, Kumar V, Sari Y Biomedicines. 2023; 11(1).

PMID: 36672619 PMC: 9855394. DOI: 10.3390/biomedicines11010111.

Early cardiac-chamber-specific fingerprints in heart failure with preserved ejection fraction detected by FTIR and Raman spectroscopic techniques.

Tombolesi N, Altara R, da Silva G, Tannous C, Zouein F, Stenslokken K Sci Rep. 2022; 12(1):3440.

PMID: 35236899 PMC: 8891318. DOI: 10.1038/s41598-022-07390-2.

Advances in Genome Editing and Application to the Generation of Genetically Modified Rat Models.

Chenouard V, Remy S, Tesson L, Menoret S, Ouisse L, Cherifi Y Front Genet. 2021; 12:615491.

PMID: 33959146 PMC: 8093876. DOI: 10.3389/fgene.2021.615491.

Genetic susceptibility of hypertension-induced kidney disease.

Zhang C, Fang X, Zhang H, Gao W, Hsu H, Roman R Physiol Rep. 2020; 9(1):e14688.

PMID: 33377622 PMC: 7772938. DOI: 10.14814/phy2.14688.

Increased Levels of Renal Lysophosphatidic Acid in Rodent Models with Renal Disease.

Hirata T, Smith S, Takahashi T, Miyata N, Roman R J Pharmacol Exp Ther. 2020; 376(2):240-249.

PMID: 33277348 PMC: 7841420. DOI: 10.1124/jpet.120.000353.

References

Lee H . Mechanisms and consequences of TGF-ß overexpression by podocytes in progressive podocyte disease. Cell Tissue Res. 2011; 347(1):129-40. PMC: 3250617. DOI: 10.1007/s00441-011-1169-7. View

Yamamoto T, Noble N, Cohen A, Nast C, Hishida A, Gold L . Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 1996; 49(2):461-9. DOI: 10.1038/ki.1996.65. View

Ziyadeh F, Hoffman B, Han D, Iglesias-de la Cruz M, Hong S, Isono M . Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000; 97(14):8015-20. PMC: 16662. DOI: 10.1073/pnas.120055097. View

Kallapur S, Ormsby I, Doetschman T . Strain dependency of TGFbeta1 function during embryogenesis. Mol Reprod Dev. 1999; 52(4):341-9. DOI: 10.1002/(SICI)1098-2795(199904)52:4<341::AID-MRD2>3.0.CO;2-N. View

Murphy S, Dahly-Vernon A, Dunn K, Chen C, Ledbetter S, Williams J . Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats. Am J Physiol Regul Integr Comp Physiol. 2012; 303(1):R57-69. PMC: 3404639. DOI: 10.1152/ajpregu.00263.2011. View

Wolf G, Chen S, Ziyadeh F . From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005; 54(6):1626-34. DOI: 10.2337/diabetes.54.6.1626. View

Border W, Ruoslahti E . Transforming growth factor-beta 1 induces extracellular matrix formation in glomerulonephritis. Cell Differ Dev. 1990; 32(3):425-31. DOI: 10.1016/0922-3371(90)90059-6. View

Ying W, Aaron K, Sanders P . Mechanism of dietary salt-mediated increase in intravascular production of TGF-beta1. Am J Physiol Renal Physiol. 2008; 295(2):F406-14. PMC: 2519184. DOI: 10.1152/ajprenal.90294.2008. View

Peters H, Noble N, Border W . Transforming growth factor-beta in human glomerular injury. Curr Opin Nephrol Hypertens. 1997; 6(4):389-93. DOI: 10.1097/00041552-199707000-00014. View

10.

Border W, Okuda S, Languino L, Sporn M, Ruoslahti E . Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 1990; 346(6282):371-4. DOI: 10.1038/346371a0. View

11.

Okuda S, Languino L, Ruoslahti E, Border W . Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest. 1990; 86(2):453-62. PMC: 296747. DOI: 10.1172/JCI114731. View

12.

Wu D, Bitzer M, Ju W, Mundel P, Bottinger E . TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol. 2005; 16(11):3211-21. DOI: 10.1681/ASN.2004121055. View

13.

Chen S, Iglesias-de la Cruz M, Jim B, Hong S, Isono M, Ziyadeh F . Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun. 2002; 300(1):16-22. DOI: 10.1016/s0006-291x(02)02708-0. View

14.

Sharma K, McGowan T . TGF-beta in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Rev. 2000; 11(1-2):115-23. DOI: 10.1016/s1359-6101(99)00035-0. View

15.

Bottinger E, Bitzer M . TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002; 13(10):2600-10. DOI: 10.1097/01.asn.0000033611.79556.ae. View

16.

Border W, Noble N, Yamamoto T, Harper J, Yamaguchi Y, Pierschbacher M . Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992; 360(6402):361-4. DOI: 10.1038/360361a0. View

17.

Geurts A, Cost G, Freyvert Y, Zeitler B, Miller J, Choi V . Knockout rats via embryo microinjection of zinc-finger nucleases. Science. 2009; 325(5939):433. PMC: 2831805. DOI: 10.1126/science.1172447. View

18.

Sharma K, Ziyadeh F . Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol. 1994; 267(6 Pt 2):F1094-01. DOI: 10.1152/ajprenal.1994.267.6.F1094. View

19.

Geurts A, Cost G, Remy S, Cui X, Tesson L, Usal C . Generation of gene-specific mutated rats using zinc-finger nucleases. Methods Mol Biol. 2009; 597:211-25. DOI: 10.1007/978-1-60327-389-3_15. View

20.

Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M . Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol. 2003; 14(7):1816-24. DOI: 10.1097/01.asn.0000074238.61967.b7. View